MAYO CLINIC HEALTH LETTER VOLUME 27 NUMBER 3 MARCH 2009 Deep vein is only one of the many situations thatmay increase your risk of DVT. Inside this issue People who develop DVT are often predisposed to quicker clotting. HEALTH TIPS . . . . . . . 3 That's often coupled with some cir- Luggage without pain.
Most often, when a man first has problems with lowered potency or with sexual dysfunction buy viagra australia shipping to pharmacies, paying purveyors, training personnel, or having a huge advertising budget.
5th Annual European Congress of Rheumatology • June 9 – 12, 2004 • ICC Building • Berlin
Professor Smolen Hosts Minister Bulmahn
Similarly High Risk
At Opening Ceremony of the Congress
Of MI in Diabetics,
Patients With RA
Professor Josef S. Smolen,
MD, President of EULAR,
presented a bouquet to
Reports presented at the 5th Annu- al European Congress of Rheuma-tology underscore the importance Edelgard Bulmahn, Federal
of aggressively managing cardiovascular Minister of Education and
disease risk among patients with rheuma- Friday & Saturday Edition
June 11 & 12, 2004
following her address at the
In one study of 1991-2001 data from opening ceremony on
the Nationwide Inpatient Sample, the largest inpatient database in the USA, Friday, 10:15 – 12:15
Minister Bulmahn pledged
Gurkipal Singh, MD, of the Department her support in response to
Top Abstract Session
of Rheumatology at Stanford University Cutting edge in rheumatology 3 Professor Smolen's request
in California, USA, and colleagues found for funding of rheumatology
that in 1991, patients with diabetes were Advances in RA therapy FOTO KIRSCH research.
70% more likely to die if admitted to a Late breaking abstracts hospital with an acute myocardial infarc- Advances in back pain and rehabilitation tion (AMI) compared to patients with EULAR Meritorious Service Awards In Rheumatology
Advances in genetics - a molecular basis of rheumatoid arthritis. However, by 2001 inflammatory diseases Hall 14.2
this difference in fatality rates from AMI Advances in osteoporosis Hall 15.2
had diminished, with 7.6% of RA pa- Advances in heterogeneity in cytokine contribution PhD, of the
tients dying from AMI compared with Advances in epidemiology University of Mainz,
7.7% of diabetes patients.
Advances in Social Leagues Germany, and Kimmo
Mortality rates from AMI among dia- Advances in infection related Aho, MD, of the
betics had decreased by 30%, from 11% rheumatic diseases in 1991, Dr. Singh observed, and at the Advances in scleroderma same time rates of AMI requiring hospi- Advances in RA clinical pictures Advances in SLE - new and old therapies talizations in this population had stabi- Advances in SPA - clinical and were presented with
lized to about 4%. therapeutic challenges Rates of AMI requiring hospitalization Meet the Standing Committee
FOTO KIRSCH Awards.
Continued on page 4 Allied Health Professional round table Friday, 14:00 – 15:30
Zoledronic Acid Linked to Slowed Bone Erosion in RA
State-of-the-Art / Best Practice
Systemic rheumatic diseases: stricted and use of other disease modi- No renal abnormalities developed in ei- treatment related morbidity The bisphosphonate zoledronic acid appeared to slow the progression of fying agents was not allowed.
bone erosions in patients with rheuma- Comparisons of MRI studies taken at In six previous trials the bisphospho- European clinical trials in SLE toid arthritis, according to findings of baseline and again at 26 weeks indicat- nates pamidronate, alendronate, and clo- Neuro-endocrine-immune interactions a small study from Leeds University, ed a 61% decrease in the mean change dronate had no significant effect on RA in the rheumatic diseases Hall 15.2
of hand and wrist erosions among pa- Sjoegren's syndrome During Thursday's Cutting Edge in tients in the zoledronic acid group com- "The combination of methotrexate Joint Session Clinical / AHP / SL
Rheumatology session, Steven Jarrett, pared with those on placebo, (0.9±1.6 vs with a potent bisphosphonate in early Rehabilitation in rheumatology MD, unveiled the results of the 6-month RA may be entirely comparable to bio- Challenges in Clinical Practice
trial of zoledronic acid, which is the first Much of this "difference in mean logical therapy," Walter P. Maksy- Infectious complications of inflammatory in the class of bisphosphonate agents change was attributable to the reduction mowych, MB, FRCP, professor of med- rheumatic conditions Hall 14.2
shown to prevent bone damage.
of erosion progression observed in the icine in the Division of Rheumatology It may become standard for all RA pa- wrist (0.7±1.5 with zoledronic acid and at the University of Alberta, Edmonton, Joint destruction tients to "get an infusion to stabilize 2.0±3.0 with placebo," according to the Canada, noted in an interview. Such an Int'l Forum for Young Rheumatologists
Discussion forum for young rheumatologists: bone," lead investigator Paul Emery, option would carry "significant cost im- lessons from animal models - pathogenesis Hall 10
MD, FRCP, said in an interview prior to In addition, 33% of patients on zole- plications in view of the expense of bio- the 5th Annual European Congress of dronic acid had evidence of new bone logicals," However, "further clinical tri- Citrullination of proteins; a clue to RA? Rheumatology. However, he stressed edema compared with 57% of patients als are clearly warranted." Invited Special Interest Groups
that this approach is still hypothetical at Current trends in rheumatology outcome Three of the 18 patients (16%) treat- Vienna to Host Congress in 2005
In the study, 39 patients were ran- ed with zoledronic acid had a decrease in Now is the time to mark your calen- Meet the Standing Committee
domized to receive 5 mg of zoledronic total number of erosions compared with dars to set aside 8-11 June 2005, Electronic data collection acid or a placebo given parenterally at measures at baseline. None of the pa- the dates of the 6th annual Euro- baseline and again at 13 weeks. All pa- tients on placebo showed such improve- pean Congress of Rheumatology, to How to diagnose osteoporosis 2 tients also received methotrexate 7.5 to be held in Vienna. We look forwardto seeing you there! Continued on page 2 20 mg weekly. Use of intramuscular or Tolerability of zoledronic acid was intra-articular corticosteroids was re- comparable to that seen with placebo.
Friday • Saturday
Scientific Programme continued from page 1
EULAR Prize, Young Investigator Award Winners
Basic immunology course for clinicians 2 Detection and identification of crystals in ment of inflammatory diseases. Specifi- istics of this antibody reaction in rela- synovial fluid: an introductory course 2 At Wednesday evening's opening ceremonies of the 5th annual cally, Dr. Hofmann is focusing on the tion to clinical outcome, will open new Friday, 16:00 – 17:30
European Congress of Rheuma- bond between steroid derivatives and the avenues for the development of novel di- tology, EULAR President Josef Smolen agnostic tools and could lead to a bet- State-of-the-Art / Best Practice
presented EUR 180,000 in award prizes. ter understanding of the processes in- Current trends in osteoarthritis Awards included the prestigious volved in the emergence and progression Paediatric rheumatology for adult rheumatologists: EULAR Prize 2004, the 3 EULAR transition to adulthood Young Investigator Awards, the have been suc- Joint Session Clinical / AHP / SL
EULAR/Bristol-Myers Squibb Young Albert J.W. Zendman, PhD, of the De-
Sleep and fatigue in rheumatic disease Investigator Award as well as the 12 for treatment of partment of Autoimmune Biochemistry EULAR/Abbott Abstract Prizes for Clin- at the University of Nijmegen, The Vascular issues in systemic sclerosis Hall 14.2
ical Medicine (6) and Basic Science (6).
Regional musculoskeletal pain Hall 15.2
Here's a look at some of the winners. Skin and the rheumatic diseases EULAR Prize 2004 (EUR 30,000)
as well as heart conditions such as sys- This year's EULAR Prize was presented temic sclerosis, myocarditis and as pro- role of citrulli- Int'l Forum for Young Rheumatologists
to Professor Piet L. C. M. van Riel, MD,
phylactic treatment to protect cardiac Discussion forum for young rheumatologists: function. Recently, a new steroid drug lessons from animal models - pathogenesis (cont'd) and new therapeutic principles that modifies this receptor has been Challenges in Clinical Practice
found to be effective and induce rela- The role of surgery in rheumatology: tively mild side effects. to cut or not to cut In order to understand the effects of this drug on the receptor, Dr. Hof- ment of rheumatoid arthritis. In this Rheumatoid arthritis; from bench to clinic mann's team will perform biophysical study, he focuses on the peptidylarginine Meet the Standing Committee
experiments and create a three-dimen- deiminase enzymes (PAD) that are re- Cutting edge science—from the industrial sional model of the crystal structure as sponsible for the production of these au- bench to the patient. Scientists from it bines to the receptor. They will also toantigenic triggers. One approach in- academia meet colleagues from industry explore the molecular mechanisms of the volves studying the effect of and use of the Disease Activity Score receptor itself. overexpression (adenoviral) of PAD in Practical tools to assess disease outcome (DAS) and EULAR response criteria for The goal of this work is to form the mouse models of rheumatoid. Addition- and functioning in clinical practice and research 2 the clinical assessment of rheumatoid basis for developing steroid derivatives ally, PAD mutants are generated for Capillaroscopy and rheumatology 2 arthritis. The DAS is a continuous com- that maximize efficacy and minimize structure and function analysis.
MRI in inflammatory joint diseases 2 posite measure of swollen joints, tender adverse effects.
EULAR/Bristol-Myers Squibb Young
Saturday, 10:15 – 12:15
joints, acute phase response and gener-al health, which was designed to provide Floris Alexander van Gaalen, MD, of the
Investigator Award (EUR 30,000)
State-of-the-Art / Best Practice
a more accurate description of RA dis- Department of Rheumatology at Leiden Rik Lories, MD, PhD, receives his award
ease activity than each of the activity University Medical Centre, The Nether- for work investigating embryonic sig- variables individually. lands, received an award for his work in Early and undifferentiated inflammatory arthritis Hall 2
The introduction of a number of new the application of micro-array technol- Glucocorticoids update 2004 EUSTAR scientific session Hall 14.2
effective anti-rheumatic agents has led to ic arthritis. Dr.
Back pain - frequent problem, but still the need for a revision of current disease difficult to handle activity assessment tools, Profesor van Riel noted in his applicatipon for the Challenges in Clinical Practice
award. He and his colleagues are currently Hall 15.2
validating the use of the DAS and the EU- LAR response criteria in clinical trials.
Gene directed identification of new inflammatory pathways Young Investigator Awards
Allied Health Professionals
then subsequently his PhD in 2003 for Developing guidance for practioners in the assessment, management and monitoring of , PhD, of the School his dissertation on "Bone Morphogenetic biological therapies in inflammatory arthritis Hall 6
of Biological Sciences and the Institute Dr. van Gaalen says he will use his Protein Signaling in Chronic Arthritis." of Cell and Molecular Biology at the award "to study the fine-specificity, Making services more accessible to University of Edinburgh, Scotland, re- avidity, and isotopes of the anti-cit- For the 12 Abbott Award Winners, please ethnic minority groups ceived an award for his work in devel- rulline antibody response." see page 14 of the Wednesday–Thursday oping steroid derivatives for the treat- An in depth analysis of the character- edition of EULAR CONGRESS NEWS. Inflammation models in paediatric EULAR Celebrates Award Winners at Opening Ceremony
Controversial issues in musculoskeletal Joint-examination taught by patients with RA; another way of teaching health professionals 2 VIP 2
Federal Minister of
and Professor Josef S.
Services on Offer in the Exhibition Areas
A Business Centre and Message Centre are
Smolen, MD, Presi-
being operated and sponsored by Pfizer at dent of EULAR, pose
their exhibit stand 12/41. This site offers a with the winners of
meeting point for attendees where they can the EULAR Prize, the
make use of such technology services as EULAR Young Investi-
Internet access and email, fax, photocopy- gator Awards, the
ing, and computers.
Cyber Café in the Exhibition Area
and Clinical Science
A Cyber Café is being operated and spon- Abstract Awards, and
sored by Merck Sharp & Dohme in the exhi- the EULAR Meritorious
bition area at their stand 14.1/01. Please Service Awards in
Friday • Saturday
Findings Yield Clues to Risk of Disease
Progression in Paediatric CNS Vasculitis
Friday, June 1, 2004
08.15 – 09.45, Hall 2
Risk of progression of pri- netic resonance angiography, or by Children with angiography-pos- The True Picture of Non-Specific NSAID Risk:
mary central nervous sys- brain biopsy. Progressive vasculitis itive findings and progressive dis- Seeing is Believing
tem vasculitis in children was defined as progression of steno- ease were more likely to present can be predicted using clinical, ra- sis at more than 3 months after the with neurocognitive dysfunction, Why Should Rheumatologists Care About GI Risk? diological and histological find- initial angiogram.
headaches, multifocal and/or bi- ings, said Susan Benseler, MD, at The investigators stratified the lateral MR lesions and multiple, What Problems Do NSAIDs Cause in the the 5th Annual European Congress children into three groups: those bilateral or peripheral stenoses.
who were angiography-positive with Those who were angiography- Is Nonspecific NSAID-Related Intolerance "Until now, the information we non-progressive disease (42 chil- positive with non-progressive dis- had came from autopsy reports.
dren), those who were angiography- ease were more likely to present What Problems Do NSAIDs Cause in the Therefore, there have been no clin- positive with progressive disease (20 with a stroke, unifocal MR lesions, ical guidelines for treatment,"said children), and those who were an- and proximal large vessel stenoses Unraveling the Mystery Of NSAID-Related Dr. Benseler, of the Department of giography-negative (4 children).
Small Bowel Disease Paediatric Rheumatology at Uni- 08.15 – 09.45, Hall 3
versity Children's Hospital in Gala Dinner at the Deutsches Technikmuseum
Setting Higher Performance Goals for Patients with
Dr. Benseler and her colleagues Please join us tonight—Friday, 11 June—for the EULAR Gala Din-ner in the German Museum of Technology. Built in 1982, the mu- Remission in Rheumatic Disease: retrospectively studied 66 children seum is located on the original site of the Anhalter freight station, Is it a Realistic Goal? who were diagnosed with primary where you will find one of the original round train sheds intact. En- central nervous system (CNS) vas- Remission Under the Surface: Assessing and try to the engine shed to view this fascinating exhibit requires pre- culitis from 1990 through 2002. Monitoring Structural Damage in Rheumatic Disease sentation of your invitation card. The dinner itself will take place in All children had vasculitis con- the newer building of the museum. The party starts at 20:15 and is Raising Patients' Expectations in the Treatment of firmed by imaging with conven- scheduled to last until 23:00. Admission is EUR 130 per person.
Rheumatic Disease: How Much Can They Expect? tional angiography and/or mag- Improving the Value of Treatment in RA Patients Question and Answer Session Prof. Gross Focuses
Similarly High Risk Of MI in Diabetics
Continued from page 1 08.15 – 09.45, Hall 14/2
among patients with RA, large health insurance compa- Paracetamol plus Tramadol: A New Option in Treating
meanwhile, increased by 47% ny databases, which included Training in Germany
from 2,748 to 5,368 cases.
data on 41,885 DMARD Chairman's introduction "Significant declines in AMI The Significance of Combining Analgesics in Professor Wolfgang L. Gross, MD, Presi- case-fatality rates have only Among the DMARD users Musculoskeletal Pain dent of the German Society for Rheuma- occurred in patients with [di- there were 268 cases of AMI tology and President of the EULAR 2004 abetes] perhaps because of ear- from 1998 to 2001, repre- Pain Relief in Osteoarthritis: The Rationale for Local Organizing Committee noted in a ly recognition and aggressive senting a rate of 5.2 per 1,000 Combination Therapy press conference on Thursday the challenge preventive and therapeutic patients per year. Quality-of-Life in Low-Back Pain: A Relevant of assuring that all measures," Dr. Singh said. He In a comparison of each Outcome of Pain Therapy stressed that patients with RA AMI case with 10 randomly 08.15 – 09.45, Hall 7
tients in Germany presenting with signs and selected controls, current use Osteoarthritis- New Etiologic and Therapeutics Insights
symptoms of AMI should be of all DMARDs, including New Concepts and New Targets in care. Many patients stratified as having a risk lev- Pain and Inflammation who go to general- el similar to that of diabetic and anti-TNF-alpha agents Inflammation and Osteoarthritis ists receive inade- patients with AMI.
was associated with a 40% re- quate drug thera- In a second study, Canadian duction in the risk of AMI.
Structure Modification and Assessment—Imaging and Biomarkers researchers reported that the "We don't know if this is an use of disease-modifying an- effect of the [DMARD] itself Panel Discussion—Question and Answer Session tirheumatic drugs (DMARDs) or an indirect effect," he said 18.00 – 19.30, Hall 2
ESSEX Pharma GmbH
who go to rheuma- was associated with a lower risk Possibly, the drugs reduce dis- Improving Outcomes in the Spondyloarthropathies:
tologists. A new government initiative of AMI in patients with RA.
ease activity and this reduction What's New? What's Controversial? What's Practical? aimed at establishing an independent con- Samy Suissa, PhD, Profes- is providing the benefit. Intensive Management of the tinuous medical education system in Ger- sor of Clinical Epidemiology The use of selective COX-2 Spondyloarthropathies: Why We Need To many should help to promote standards of at Royal Victoria Hospital, inhibitors was associated with Consider a New Treatment Paradigm? care. More focus on rheumatology training McGill University Health a 70% increase in AMI risk.
TNF-Inhibitors for the Treatment of also is needed; only 7 of 35 German uni- Centre in Montreal, Canada, This increased risk was not Spondyloarthropathies: What Are The Differences? versity clinics have a chair devoted to and colleagues conducted a seen with traditional NSAIDS rheumatology, Professor Gross said.
case-control study using two or glucocorticoids.
Managing Gut and Eye Involvement Related To Spondyloarthropathies: When Is IntensiveTreatment Warranted? EULAR 2004
EUSTAR Group Announces Initial Data
Achieving and Maintaining Remission In PsoriaticDisease: How Effective Are Biologics on Joint and Over 9,300 partici- The 9-month results from the new centers, there are now 54 active centers Skin Manifestations? EULAR Scleroderma Trial and Re- with a total of more than 1200 patients.
Question and Answer Session search group (EUSTAR) will be present- In addition to Professor Matucci Cerinic countries are repre- 18.00 – 19.30, Hall 3
ed on Saturday from 10:15-12:15 in Hall (chair) the elected members of the EU- sented at this year's Selective Co-Stimulation Modulation: An Emerging New
14.2, according to Marco Matucci STAR group include Alan Tyndal, MD, Congress, according Strategy in Rheumatoid Arthritis Therapy
Cerinic, MD, PhD, professor of rheuma- (secretary), Ulf Muller Ladner, MD, to Ernst Isler, Con- Chairman's Opening gress Coordinator.
tology and medicine at the University of (treasurer), and its four counselors: Chris Florence, and EULAR General Secretary.
Denton, Dominique Farge, Otylia Underlying Immune Mechanisms in RA gress to date addi- The mission of EUSTAR is to foster Kowal, and Laszlo Czirijak. A EUSTAR Targeting T-Cell Activation Through Selective tionally features the the understanding and management of course for assessment of the scleroderma most extensive con- scleroderma throughout Europe. The patient is scheduled for January 2005 in Evolving Clinical Profile of the First in Class tent to date with group reflects the growing spirit of col- Budapest. The final announcement of nearly 300 lectures, Selective Costimulation Modulator for RA Therapy 187 oral abstracts, laboration in research, Professor the meeting will be made at the begin- and 114 sessions.
Matucci Cerinic explained. Initiated in ning of October, and registration and ad- 2003, EUSTAR patient data collection ditional information will be posted at the began in September. Of 107 affiliated group's website, www.eustar.org. Friday • Saturday
2004 Exhibitors AXIS-SHIELD PLC . . . . . . . . . . . . . . . . . 12/02 Seiyaku, Ltd. Centocor Inc. a wholly owned subsidiary of Johnson & Johnson, has
The Technology Park, Dundee DD2 1SW, United Kingdom — Axis-Shield is marketing rights to the product in the U.S.
a global manufacturer of in-vitro diagnostic kits with a focus on new markers incardiovascular, rheumatoid, infectious and alcohol-related diseases, diabetes, demen- tia, and near patient testing to facilitate improved patient management. Axis- Witikonerstrasse 15, 8032 Zürich, Switzerland — The aims of EULAR are to Shield has introduced the Diastat Anti-CCP (cyclic citrulinated peptide) ELISA reduce the impact of rheumatic diseases on the individual and society and to im- c/o Professor Anthony Woolf, Royal Cornwall Hospitals NHS Trust, test. This novel marker has been shown to be present very early in the disease, very prove the social position of people with rheumatic diseases in Europe. Therefore Truro TR1 3LJ, United Kingdom — The aim of Arthritis Action is to raise the specific (98%) and as sensitive as the RF(IgM)test (80%). Furthermore, antibody EULAR shall stimulate, promote, and support the research, prevention, treatment, profile, awareness and understanding of musculoskeletal conditions (arthritis and presence has been shown to be correlated to disease severity. News releases and oth- and rehabilitation of rheumatic diseases. For this purpose, rheumatic diseases shall pain) and their impact on people in Europe. The initiative is driven by a group of er company information are available at www.axis-shield.com.
be defined as diseases of connective tissue and medical disorders of the muscu- leading physicians and academics specialising in the management of musculoskele- loskeletal or locomotor system.
tal conditions. Its Patient Partners effort is the only global, patient-led education BIONICHE PHARMA GROUP . . . . . . . . . . . . . . 12/15
programme of its kind. The programme involves more than 600 people with arthri- Unit 6, Casla Ind. Est, Casla, Galway, Ireland — Suplasyn md is a sterile EUROIMMUN . . . . . . . . . . . . . . . . . . 15.1/04
tis who are specially trained to educate medical students and physicians on con- sodium hyaluronate solution uniquely designed for viscoelastic supplementation of Seekamp 31, 23560 Lüebeck, Germany — EUROIMMUN produces an extensive ducting musculoskeletal examinations.
the small synovial joints. Available in prefilled syringes (7 mg/0.7 mL). Suplasyn is range of indirect immunofluorescence, microplate ELISA, immunoblot (Euroassay, a sterile sodium hyaluronate solution for synovial fluid replacement therapy in larg- Euroline, Westernblot), and radioimmunoassay test systems for laboratory diagnostics ABBOTT LABORATORIES . . . . . . . . . . . . . . 15.1/06
er joints such as the knee. Available in prefilled syringes (20 mg/2 mL). Suplasyn in the areas of autoimmunity, infectious serology and allergology. Numerous patented 200 Abbott Park Road, Abbott Park, IL 60064, USA — Abbott Laborato- and Suplasyn md have been shown to be beneficial in osteoarthritis for the manage- technologies have been developed, among them Biochip technology and Titerplane ries is marketing Adalimumab (Humira), a fully human Anti-TNF alpha mono- ment of pain and improvement in physical function of joints.
technique, which considerably simplify and standardize immunological analyses. EU- clonal Antibody, for the treatment of rheumatoid arthritis (RA). Humira has shown ROIMMUN supplies its products and services to over 2,000 laboratories worldwide.
impressive as well as sustained clinical effects in an extensive clinical development BIOSCIENCE EDIPRINT INC. . . . . . . . . . . . . . 12/08
programme. In addition, Humira provides convenience to the patients with a 16 rue A.-Gavard, 1227 Geneva, Switzerland — Bioscience Ediprint Inc. is ready-to-use syringe and every-other-week dosing. Humira is indicated in EU for an international publisher specializing in medical publications for hospitals, univer- Stuhlsatzenhausweg 69, 66123 Saarbrücken, Germany — Eyeled GmbH of- the treatment of moderate to severe, active RA in adult patients when the response sities, clinics, and research centers. Special attention is given to official institutions fers information solutions for PDAs, Smart Phones, and Web Pads. We develop to disease-modifying antirheumatic drugs including MTX has been inadequate. To (governmental and nongovernmental) and to pharmaceutical companies. Please visit customized and user-oriented applications of the very highest quality. The wide- ensure maximum efficacy, Humira is given in combination with MTX. Humira can our stand no 12/08 and ask for the latest samples of our publications.
ranging technological expertise of our specialists enable them to create streamlined be given as monotherapy in case of intolerance to MTX or when continued treat- solutions which are then integrated in the existing IT environment. Our activities ment with MTX is inappropriate.
BOEHRINGER INGELHEIM . . . . . . . . . . . . . . 15.1/09
include strategy, technology, and innovation counselling; company solutions; com- Binger Straße, 55216 Ingelheim am Rheim Germany — Mobic (meloxicam), munication solutions; and visitor information systems for exhibitions, congresses, ACTELION PHARMACEUTICALS . . . . . . . . . . . . 15.1/05
a nonsteroidal anti-inflammatory drug indicated for symptomatic treatment of Gewerbestrasse 16, 4123 Allschwil, Switzerland — Actelion Ltd, a biophar- painful osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. Contraindi- maceutical company, is a leading player in innovative science related to the en- cations: hypersensitivity; cross sensitivity to acetylsalicylic acid and other nsaids; FIDIA FARMACEUTICI S.P.A. . . . . . . . . . . . . . 17/13
dothelium—the single layer of cells separating every blood vessel from the blood asthma, nasal polyps, angio-oedema or urticaria following the administration of Via Ponte della Fabbrica 3/A, 35031 Abano Terme PD, Italy — Fidia and stream. With a focus on the discovery, development, and marketing of innovative acetylsalicylic acid or other NSAIDs; active peptic ulceration; severe hepatic or re- its associated companies operate worldwide to develop and market innovative drugs for unmet medical needs, Actelion's first drug, Tracleer, an oral dual endothe- nal insufficiency; pregnancy or breastfeeding; children under 12 years.
health care products mainly based on naturally occurring hyaluronic acid (HA) and lin receptor antagonist, has been approved for the treatment of pulmonary arterial its derivatives. Fidia has developed proprietary breakthrough technology in the BRISTOL-MYERS SQUIBB . . . . . . . . . . . . . . 17/03
field of human tissue regeneration—from skin and cartilage to connective tissue— 3 Rue Joseph Monier, 92506 Rueil Malmaison France — Bristol-Myers Squibb for treating severe pathologies such as knee OA with its worldwide available i.a. in- makes a significant contribution to rheumatoid arthritis therapy through its pain jectable product Hyalgan/Hyalart.
General Mitre 151, 8022 Barcelona, Spain — ALMIRALL the first Spanish management and innovative research. Bristol-Myers Squibb leads Europe with its multinational pharmaceutical company with large experience in R&D, provides so- paracetamol brands: Efferalgan, Dafalgan, and Perfalgan. The company is evaluating FÖRDERVEREIN BERLINER SCHLOSS E.V. . . . . . . . . 17/48
ciety with innovative drugs to combat disease, thus helping to improve health and T-cell costimulation modulation with abatacept as a unique therapeutic strategy in Postfach 560220, 22551 Hamburg, Germany — The Berlin Castle was the quality of life. One of its drugs is aceclofenac, an NSAID launched in over 60 coun- rheumatoid arthritis. Bristol-Myers Squibb is a global pharmaceutical and related centre of the city of Berlin for many centuries. Dating back to the 15th century, it tries and used by more than 75 million people worldwide since its launch. Many health care products company whose mission is to extend and enhance human life.
was turned into a remarkable baroque castle over time, and it served as the resi- international clinical trials with aceclofenac demonstrate an equal efficacy to other dence for various royal dynasties. In February of 1945, a fire following an air raid NSAIDs but with an improved tolerability profile.
BRITISH SOCIETY FOR RHEUMATOLOGY . . . . . . . . . 17/38
almost completely destroyed the building. The government of the GDR later tore 41 Eagle Street, London WC1R 4TL, United Kingdom — BSR is the UK down the ruins to form a large square in the centre of East Berlin. After the fall of AMERICAN COLLEGE OF RHEUMATOLOGY . . . . . . . . . 17/29
professional organisation for those working in rheumatology, with 1400 members the Berlin Wall, plans came up to reconstruct the original Berlin Castle. Despite 1800 Century Place, Suite 250, Atlanta, GA 30345, USA — The Ameri- (including 450 international). BSR publishes a wide range of information on ser- the support of the German Parliament, the Senate of Berlin, and other political and can College of Rheumatology (ACR) is the professional organisation of physicians, vice, guild, and clinical issues, in addition to its journal "Rheumatology," and it cultural organisations, the funding of this plan remains critical. The "Foerderverein health professionals, and scientists that advances rheumatology through pro- maintains an extensive website. The society also manages it's flagship project, the Berliner Schloss" is one of the fund-raising initiatives for this project. grammes of education, research and advocacy. Stop by the ACR's exhibit stand for Biologics Register, which monitors the treatment of patients on anti-TNF alpha information on the 68th Annual Scientific Meeting, Oct. 16-21, 2004, San Anto- drugs. Visit the BSR's stand for copies of our literature and information about the FRESENIUS MEDICAL CARE DEUTSCHLAND GMB . . . . . . 15.1/01
nio, Texas. The ACR's website is www.rheumatology.org.
journal "Rheumatology." Else-Kroener-Strasse 1, 61352 Bad Homburg Germany — Fresenius MedicalCare recently incorporated adsorber therapy into its business. Immunoadsorption AMGEN EUROPE B.V. . . . . . . . . . . . . . . . 12/06
CSC PHARMACEUTICALS HANDELS GMBH . . . . . . . . . 17/13
therapy using Prosorba offers new perspectives to patients with moderate to severe, Minervum 7061, 4817 ZK Breda, Netherlands — The world's largest Gewerbestrasse 18-20, 2102 Bisamberg, Vienna, Austria — CSC Pharmaceu- active rheumatoid arthritis unresponsive or contraindicated to standard drug thera- biotechnology company, Amgen Inc. strives to dramatically improve people's lives.
ticals Handels GmbH is a pharmaceutical company based in Austria with opera- pies. Prosorba fulfills the requirements of "evidence based medicine". A clinical trial The company discovers, develops, and delivers important human therapeutics based tions in Central and Eastern European countries. Rheumatology is one of the main has shown that in 42% of patients who do not respond to medication, the Prosorba on advances in cellular and molecular biology including Epogen (Epoetin alfa), therapeutic areas of our interest. Information about products will be available at our therapy resulted in significantly reduced symptoms.
Aranesp (darbepoetin alfa), Neupogen (Filgrastim), Neulasta (pegfilgrastim), Enbrel stand: Aulin nimesulide, DayRun oxaprozin, FlexodonA glucosamine + chondroi- (etanercept), and Kineret (anakinra). Amgen's dedication to science and innovation tine sulphate, Hyalgan hyaluronic acid, Hyalograft cartilage engineering, Piascle- GE HEALTHCARE LUNAR . . . . . . . . . . . . . . . 12/14
is driven by a commitment to serve patients.
dine ASU, Prontoket ketoprofen spray, viatromb heparin liposomic spray.
Kouterveldstraat 20, 1831 Diegem, Belgium — Visit GE Healthcare Lunar atbooth 12/14 to learn about our complete line of bone densitometers: Prodigy Ad- ANAMAR MEDICAL AB . . . . . . . . . . . . . . . . 12/09
DEUTSCHE RHEUMA-LIGA . . . . . . . . . . . . . . 17/32
vance, the high-end densitometer with Direct Digital Technology; DPX Bravo, a Rapsgatan 7, 75174 Uppsala, Sweden — AnaMar was founded in 1998. The Maximilianstrasse 14, 53111 Bonn, Germany — Help and self help organisa- compact solution with high quality performance; Achilles Insight, a reliable ultra- company currently employs 13 people and is situated in Uppsala and Lund, Swe- tion for people with all kind of rheumatic diseases. 250,000 individuals are mem- sonometer. In addition, GE Ultrasound Imaging systems offer excellent musculo- den. During its first years of operation AnaMar focused on the development of a ber in the organisation that works for the benefit of patients all over Germany.
skeletal imaging as well as a sensitive color and power Doppler feature.
biomarker (COMP), which currently is marketed worldwide through leading re- The organisations website is www.rheuma-liga.de and its 2004 campaign is "Die sellers such as Inova, Abbott and Pharmacia. AnaMar has also an ongoing drug de- erste Liga, wenn's um Rheuma geht," or "Approaching people with GELITA HEALTH INITIATIVE . . . . . . . . . . . . . . 17/26
velopment programme. The company has so far developed two drug concepts and arthritis/rheumatism in age of 35-50." Uferstrasse 7, 69412 Eberbach, Germany — GELITA CH alpha® is a liquid has identified a first lead structure within each of these concepts.
nutritional supplement offered in 25 mL-ampoules for daily intake. The product DEUTSCHE VEREINIGUNG MORBUS BECHTEREW . . . . . . 17/35
contains highly purified collagen hydrolysate (CH alpha) that provides the collagen ANIKA THERAPEUTICS, INC. . . . . . . . . . . . . . 12/13
Metzgergasse 16, 97421 Schweinfurt, Germany specific amino acids proline and glycine and stimulates the synthesis of the carti- 160 New Boston Street, 1801 Woburn MA, USA — Anika Therapeutics de- lage matrix. It is beneficial to those individuals suffering from degenerative joint velops, manufactures, and commercializes therapeutic products intended to repair, wear and tear and helps to regenerate stressed joint cartilage. The effects are shown protect, and heal bone, cartilage, and soft tissues. OrthoVisc is a noninflammatory, Viale Monza 133, 20125 Milano, Italy in numerous laboratory experiments and clinical trials.
highly pure, high-molecular-weight, highly concentrated, high-viscosity, non-cross- Instruments include the Videocapillaroscopic Videocap—an optical probe and po- linked hyaluronan for intra-articular injection. It serves as a viscoelastic supplement larized light videocapillaroscopy in microvascular clinical practice and research— GENESIS DIAGNOSTICS LTD . . . . . . . . . . . . . . 17/24
or as a replacement for synovial fluid in human joints. OrthoVisc is intended to re- and the Videocap Net—the first digital handheld immersion and polarized light Eden Research Park, Henry Crabb Road, CB6 1SE Littleport, Cam- lieve pain and improve joint mobility in patients who are suffering from os- capillaroscope for specialized medicine. The company also publishes the Atlas of bridgeshire, United Kingdom — Genesis Diagnostics are a specialist company in Capillaroscopy. The aim of this atlas is to provide a gallery (676 high-quality colour autoimmune kit production and are the first company to offer a citrullinated filag- pictures) of the most representative capillaroscopic pictures in patients with grin antibodies (CPA) test panel. Genesis have pioneered the development of class rheumatic diseases.
specific CPA-IgG, CPA-IgM, CPA-IgG and CPA Screening kits. Since some RA Kangnam St. Mary's Hospital, 505 Banpo-dong 137-701 Seoul, South Korea patients do not have IgG antibodies, the importance of measuring CPA-IgM and — The 11th Asia Pacific League of Associations for Rheumatology congress IgA is clear. The Genesis CPA kits have high sensitivity and specificity for the early (APLAR 2004) will take place at Jeju Island, Korea from September 11-15, 2004.
ELI LILLY & COMPANY . . . . . . . . . . . . . . .15.1/08
detection of rheumatoid arthritis. The tests are easy to use and can be automated for The theme of this year's congress is "Future in rheumatology: from bench to bed- Lilly Corp. Center, D.C. 5016, Indianapolis, IN 46285, USA high throughput volumes.
side," and more than a hundred well-known speakers from around the world will Evista (Raloxifene HCl), the first SERM, acts through the estrogen receptor in bone attend. Also, there will be the chance to contribute to the advancement of rheuma- and affects bone-signaling molecules, resulting in decreased osteoclast activity.
GENZYME BIOSURGERY . . . . . . . . . . . . . . . 12/12
tology by exchanging your ideas and clinical experiences with other members. The Evista provides protection for postmenopausal women, without vasomotor symp- 4620 Kingsgate, Cascade Way, Oxford Business Park South, OX4 2SU Ox- organizing committee looks forward to meeting many delegates on the beautiful is- toms, who have had a vertebral fracture or are at risk for experiencing a vertebral ford, United Kingdom — Practice your intra-articular injection technique on our land of Jeju on the occasion of the 11th APLAR Congress. Official website: fracture. Forsteo (Teriparatide rDNA origin injection), the first approved bone for- interactive hip simulator and discuss the benefits of Synvisc for your OA patients on www.aplar2004.com mation agent, increases the number and activity level of osteoblasts to form new Stand 12/12. One Synvisc treatment course can relieve the pain and immobility of bone. Forsteo is indicated for patients with established/severe osteoporosis or at knee OA for up to 12 months and the product is also clinically proven and approved ASTRAZENECA . . . . . . . . . . . . . . . . . . 17/01
high risk for experiencing another vertebral or nonvertebral fracture.
for use in the hip. Effective in all disease stages, viscosupplementation with Synvisc is Pepparedsleden 1, 431 83 Mölndal, Sweden — AstraZeneca is an international ideal when patients' symptoms are not controlled by pharmaceutical therapies, when pharmaceutical company with research focused on areas of disease in which its pro- NSAIDs are contraindicated, or when surgery should be delayed or avoided.
ficiency can satisfy important medical needs. The current portfolio of products in Via Siffredi 58, 16153 Genova, Italy — Esaote, part of the Bracco Group, is a AstraZeneca's prioritised areas (gastrointestinal, cardiovascular, respiratory, global leader in research, production, and marketing of medical diagnostic equip- GRAPHNET <THE XML PEOPLE> . . . . . . . . . . . . 17/43
pain/anaesthesia/infection, oncology, and CNS) bears testimony to the AstraZeneca ment and related services. Ultrasound is the core business of Esaote with products Graphnet has a proven track record in providing information solutions to meet spe- Way in R&D. Important gastrointestinal products are Nexium, the first proton ranging from highly portable devices to high-end digital multi-application units cific clinical, financial and technical challenges that healthcare faces today. Har- pump inhibitor (PPI) developed as an isomer; Entocort; and Losec.
and dedicated systems for contrast ultrasound scanning. Esaote is a market leader in nessing over 10 years experience of working with the National Health Service in dedicated MRI with a focused attention on the application of MRI in rheumatol- the UK, Graphnet applies leading-edge XML technology and consultancy to help ogy. Esaote is actively supporting research on MRI for rheumatology pathologies in healthcare organisations reap real benefits. Healthcare is evolving fast. Graphnet 20 Avenue Raymond Aron, 92160 Antony, France — As a global pharmaceu- collaboration with major institutes mainly in Europe.
solutions are flexible and easy to migrate, delivering benefits today and paving the tical company, we offer a range of leading brands for therapeutic areas such as dia- way for the future.
betes, oncology, cardiovascular disease, allergy/respiratory, bone, and human vac- ESSEX PHARMA GMBH . . . . . . . . . . . . . . .15.1/07
cines. We have a commercial presence in approximately 85 countries and our 2000 Galloping Hill Road, K-1-3/3040, 7033 Kenilworth, NJ, USA — GRÜNENTHAL GMBH . . . . . . . . . . . . . . . . 12/03
products are available in more than 170. Arava (leflunomide) is an oral disease- Remicade is a monoclonal antibody that targets and binds to TNF-alpha. It is the Zieglerstraße 6, 52078 Aachen, Germany — Grünenthal GmbH is a research- modifying antirheumatic drug indicated for the treatment of active rheumatoid only biologic indicated for Crohn's disease, rheumatoid arthritis, and ankylosing oriented European pharmaceutical company based in Germany. Core activities are the arthritis in adults. Arava has a unique mode of action and has demonstrated a high spondylitis. Remicade is the most well characterized TNF-alpha, with over 10 years development of new analgesic medicines and the improvement of pain management by and sustained efficacy for up to 5 years. Actonel (risedronate sodium) is the only os- of clinical and safety data and more than 500,000 patients treated. It is unique quality initiatives and educational tools. Grünenthal GmbH is the originator of the teoporosis treatment that consistently provides rapid efficacy and offers fracture among available anti-TNF therapies in that it provides the convenience of in-office centrally acting analgesic tramadol (Tramal), which occupies a key role in the treat- protection within 1 year—a primary goal of osteoporosis treatment according to the treatment. Schering-Plough markets Remicade in all countries outside of the U.S., ment of moderate to severe cancer and non-cancer pain. With Transtec, an innovative International Osteoporosis Foundation.
except Japan and parts of the Far East, where Remicade in marketed by Tanabe buprenorphine patch, and Zaldiar, a rationale analgesic combination, Grünenthal en- June 11 & 12, 2004 • Berlin
5TH ANNUAL MEETING & EXHIBITION
riches the armamentarium to treat acute and chronic pain of different aetiologies. Over MERCK SHARP & DOHME . . . . . . . 14.1/01, 14.1/05, 14.1/06
and about the impact of health care policy on the specialty and the physician's prac- the years, the company has set up affiliates and strategic alliances worldwide.
One Merck Drive, Mailstop WS2C36B, 08889-0100 Whitehouse Station, tice. It is distributed in the U.S. to 10,200 physicians. Rheumatology News Inter- NJ, USA — Vioxx (rofecoxib, MSD): Rofecoxib is a powerful, once-daily COX II national, launched in February 2004, reaches 10,800 specialists in the EU and oth- HELSINN HEALTHCARE . . . . . . . . . . . . . . . . 17/13
inhibitor proven to relieve pain and inflammation for osteoarthritis, rheumatoid er European countries.
PO Box 357, 6915 Pambio-Noranco, Switzerland — Helsinn Healthcare SA arthritis and acute pain. Arcoxia (etoricoxib, MSD): Etoricoxib is a new agent for is a licensing Swiss-based pharmaceutical company. Its main focus is to develop and rapid and long lasting treatment of pain and inflammation to relieve osteoarthritis, license innovative and valuable pharmaceutical compounds from early clinical rheumatoid arthritis and acute gout. Before prescribing, consult the product circu- Via Valosa di Sopra 7/9, 20052 Monza, Italy — Rottapharm is a multina- stages of development up to the highest quality standards (European and the U.S.
lar for information.
tional pharmaceutical group with a strong presence in Europe; its original drugs are requirements). Helsinn Healthcare organises its international network of competent sold worldwide. In the rheumatic field, Rottapharm has developed and patented the and distinguished partners by offering continuous and professional support. Our MERCKLE GMBH . . . . . . . . . . . . . . . 17/04 & 17/05
original stabilized glucosamine sulfate, the first proven disease-modifying agent for main products are Nimesulide, Oxaprozin, Palonosetron, Gelclair, Fentiazac, Klean- Graf-Arco-Straße 3, 89079 Ulm, Germany — Licofelone is a novel analgesic osteoarthritis. 150 preclinical and clinical studies with more than 12,000 subjects Prep, Melatonin, and Rapolyte. www.helsinn.com.
and anti-inflammatory agent in late phase III development by Merckle GmbH and and 91 leading institutions confirmed that DONA Glucosamine Sulfate can slow its partners in the Euro Alliance: Alfa Wassermann SpA of Bologna, Italy, and Lacer down the progression of osteoarthritis when administered long term.
IBSA - LABORATOIRES GENEVRIER . . . . . . . . . . . 12/18
SA of Barcelona, Spain. Licofelone is a LOX/COX inhibitor that offers an unrivaled Via del Piano, PO Box 266, 6915 Pambio-Noranco, Switzerland — IBSA safety profile and long-term efficacy in a broad spectrum of OA patients.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY . . . . . . . 17/41
is an international pharmaceutical company fully committed to tailored therapeu- Norrebrogade 44, 8000 Aarhus, Denmark — We invite you to visit the exhib- tic solutions for osteoarthritis, including a full range of formulations and strengths NEGMA-LERADS . . . . . . . . . . . . . . . . . . 12/22
it of the Scandinavian Journal of Rheumatology. The journal publishes internation- of oral chondroitin sulphate (Condrosulf/Chondrosulf/Condral), an intra-articular Avenue de l'Europe, Toussus-Le-Noble, 78771 Magny-Les-Hameaux, France al, peer reviewed, high quality, original reports of clinical and basic research, as well hyaluronic acid (Sinovial), and an innovative, patented epolamine salt of diclofenac — Diacerein (ART50, Negma-Lerads) is a disease-modifying osteoarthritis drug as editorials, review articles, and informative case reports covering all aspects of (Flector EP). Laboratoires Genevrier is IBSA's French sister company. Osteoarthri- (DMOAD) inhibiting IL-1. Diacerein has beneficial effects on the symptoms of os- rheumatology. Subscribers have the option of free electronic access and supplements tis focused, it is a market leader in the domestic chondroprotection market.
teoarthritis (OA) such as pain and functional disability. The onset of action of the to the journal. Detailed information is available on our website: www.scand- drug is delayed (4 weeks after treatment start with an effect comparable with that of NSAIDs. Furthermore, Diacerein has beneficial structural effects in OA, as International League of Associations for Rheumatology.
shown by the 3-year randomized, placebo-controlled ECHODIAH trial in 507 pa- SCHERING DEUTSCHLAND GMBH . . . . . . . . . . . . 12/04
tients with hip OA. Indeed, the results of this trial have demonstrated that diacere- Max-Dohrn-Strasse 10, 10589 Berlin, Germany — Radiosynoviorthesis is INOVA DIAGNOSTICS, INC. . . . . . . . . . . . . . . 17/10
in significantly reduces the progression of OA measured by radiography (see legal indicated principally for the treatment of patients with rheumatoid arthritis who 10180 Scripps Ranch Blvd, 92131 San Diego CA, USA — INOVA Diagnos- specifications), with a good safety profile.
are well controlled by systemic treatment, but in whom one or few joints remain tics, Inc. develops, manufacturers, and sells a complete menu of autoimmune disease inflammatory. In this case, radiosynoviorthesis should be chosen as a local treatment diagnostic kits and components for screening and specific autoantibody determina- NEUROCHEM INC. . . . . . . . . . . . . . . . . . 12/35
(if the joints not respond to local injections of corticosteroids) with a high efficiency tions. Product lines include Quanta Lite ELISA, Nova Lite IFA, Nova Gel Ouchter- 1375 Transcanada Hwy, suite 530, H9P 2W8 Dorval, Quebec, Canada — about 76% in rheumatoid arthritis. Depending of the size of the joint, there are lony, Quanta Chek Validated Reference Panels, Quanta Plex multiplexing reagents as Neurochem is focused on the development and commercialization of innovative three emitters used for therapy: Y-90, RE-186, and Er-169.
well as related microwell, IFA and multiplexing instrumentation systems. Product therapeutics for neurological disorders. Fibrillex, designated an orphan drug, is in a groups include kits and components for rheumatoid arthritis, connective tissue disease, Phase II/III clinical trial for AA amyloidosis. Alzhemed has completed a Phase II SKLERODERMIE SELBSTHILFE E.V . . . . . . . . . . . . 17/47
coagulation, gastrointestinal, vasculitis, endocrine, and autoimmune liver disease.
clinical trial for the treatment of Alzheimer's disease. Cerebril is in a Phase II trial Am Wollhaus 2, D-74372 Heilbronn, Germany — The Sklerodermie Selb- for the prevention of hemorrhagic stroke caused by amyloid.
sthilfe ie.V. is a self-help organisation for scleroderma patients and their supporters.
INSTITUTE OF HEALTHCARE RESEARCH . . . . . . . . . . 17/28
It was founded in July 1984. In Germany there are about 40 regional groups and The Boathouse, The Embankment, Putney SW15 1LB, United Kingdom — NOVARTIS PHARMA . . . . . . . . . . . . . . . . . 17/22
more than 1,450 members. The management of the association and the leaders of IHR is a data collection agency that is involved in long-term studies. Our aim is to Lichtstrasse 35, 4056 Basel, Switzerland — Novartis AG (NYSE: NVS) is a the regional groups engage themselves on a voluntary basis. Scleroderma has been develop relationships with physicians in the UK, Germany, France, Spain, and Italy.
world leader in pharmaceuticals and consumer health. In 2003, the group's busi- known for centuries, but the real origin of this orphan disease is still unknown de- Data are collected continuously, in strict confidence, to the highest standards in the nesses achieved sales of USD 24.9 billion and a net income of USD 5.0 billion. The spite a very intensive research in the last two decades. The objectives of the organi- industry. In return, Physicians are rewarded through our Medical Incentives Plan - Group invested approximately USD 3.8 billion in R&D. Headquartered in Basel, sation are layed down in the statutes: information and public relations, medical care attendance at conferences, a selection of gifts, savings plans, donations to charity.
Switzerland, Novartis Group companies employ about 78,500 people and operate and social welfare to the patients, arrangement of social help and services, promo- in over 140 countries around the world. For further information, please consult tion of scientific and research work. The objectives of the management and espe- cially of the regional groups are to help the patients out of their isolation and to INTERNATIONAL JOURNAL OF ADVANCES IN RHEUMATOLOGY . . 12/01
inform them how to live, to exchange of views and experiences with other patients, and to give practical advice and help for day-to-day life.
JOINT AND BONE.ORG . . . . . . . . . . . . . . . . 17/07
17000 Commerce Parkway, Suite C, Mount Laurel, NJ 08054, USA —The OsteoArthritis Research Society International (OARSI) is a nonprofit scientific SLACK INCORPORATED . . . . . . . . . . . . . . . 12/05
organisation formed to promote and advance research for the prevention and treat- 6900 Grove Road, Thorofare, NJ 08086, USA — SLACK Incorporated in- Cluster Park, Leuvenstesteenweg 369, 1932 Zaventem, Belgium — Kyphon ment of osteoarthritis. Visit us at www.oarsi.org.
vites you to visit Booth 12/05 to get your free issue of Orthopaedics Today Interna- focuses its energy in revolutionising spine therapy. Balloon Kyphoplasty is a mini- tional Edition, Global News in Musculoskeletal Health & Disease, the only news- mally invasive procedure to treat vertebral body compression fractures. The tech- OXFORD IMMUNOTEC LTD . . . . . . . . . . . . . . 17/49
paper serving the global orthopaedic community. It covers news of the latest studies nique is designed to reduce and stabilize the fracture in a controlled way, to correct 91 Milton Park, Abingdon OX14 4RY, United Kingdom — The Oxford Im- and techniques in orthopaedic surgery and updates from scientific meetings around spinal deformity, to prevent new fractures and to provide immediate pain relief and munotec in-vitro diagnostic test for tuberculosis will replace the tuberculin skin the world. Also see Orthopedics and the Journal of Knee Surgery. Sign up for our improved quality of life.
test as it is more sensitive and more specific. It can be used to screen patients for free news wire service at orthopedicstoday.com.
TB prior to anti-TNF alpha therapy. The modified Elispot methodology identifies LABORATOIRES EXPANSCIENCE . . . . . . . . . . . . 17/11
individual effector T cells that release interferon gamma when challenged by specif- THE ANNALS OF THE RHEUMATIC DISEASES —
10 Avenue de l'Arche, La Défense, 92419 Courbevoie, France — ic M. tuberculosis antigens. The presence of these T cells indicates TB infection THE EULAR JOURNAL . . . . . . . . . . . . . . . . 15.1/02
EXPANSCIENCE Laboratories offer unique pharmaceutical specialities in rheuma- even when there are no clinical symptoms of the active disease. The test has great Editorial, BMJ Publishing Group, BMA House, Tavistock Square, London tology: Piascledine 300, the leader in the osteoarthritis treatment as a SYSADOA; sensitivity as it can identify a few T cells sensitive to M. tuberculosis antigens. The WC1H 9JR, United Kingdom — ARD is the official journal of EULAR - the Fixical and Fixical vitamine D3, for calcium deficiencies and osteoporosis; and test is highly specific due to the use of specific antigens that are not found in the European League Against Rheumatism, and all (scientific) delegates to the annual Takadol 100 mg, tramadol for pain control. As a leader in the treatment of os- BCG vaccine or most environmental mycobacteria. EULAR congress receive a complimentary 12-month subscription to the journal.
teoarthritis, Expanscience Laboratories can offer doctors and their patients training The Annals of the Rheumatic Disease is an international journal committed to pro- and information resources of very high scientific quality.
PARE MANIFESTO . . . . . . . . . . . . . . . . . 17/34
moting the highest standards of scientific exchange and education. It covers all as- c/o Arthritis Care, 18 Stephenson Way, London NW1 2HD, United King- pects of rheumatology, and publishes basic, clinical, and translational scientific re- LEICA MICROSYSTEMS . . . . . . . . . . . . . . . . 17/30
dom — The PARE Manifesto has been developed by people with arthritis/rheuma- search. Concise scientific communication is encouraged and peer reviewed Ernst-Leitz-Straße 17-37, 35578 Wetzlar, Germany — Leica Microsystems tism in Europe representing: Arthritis & Rheumatism International (ARI), Interna- proceedings of international meetings are featured. The journal was first published is a leading global innovator, manufacturer, and supplier of high-precision optical tional Organisation of Youth with Rheumatism (IOYR), and EULAR Social in 1939 and has an authorative global Editorial Board and a growing international solutions for the analysis of microstructures. Leica Microsystems manufactures a Leagues (EULAR). The aim of the PARE Manifesto is to raise greater awareness of comprehensive portfolio of products used in a wide variety of applications requiring arthritis/rheumatism and to empower people with arthritis/rheumatism in Europe microscopic vision, measurement, analysis, and lithography, including applications to become involved in the development of policies, health care provision, and social THE PANAMERICAN LEAGUE OF
in the life sciences (such as biotechnology research and medicine), the materials sci- and community services that affect the quality of their lives.
ASSOCIATIONS FOR RHEUMATOLOGY . . . . . . . . . . . 17/37
ences, industrial inspection, and the semiconductor manufacturing industry.
Hermilio Hernandez 150, Lima 27, Peru — The Panamerican League of Asso- PFIZER . . . . . . . . . . . . . . 12/16 + 12/17 + 12/41
ciations for Rheumatology (PANLAR)was established in 1943. PANLAR is orga- LUPUS ERYTHEMATODES SELBSTHILFEGEMEINSCHAFT E.V. . . 17/40
c/o Parexell-MMS Ltd, 3 Liverpool Gardens, Wothing, West Sussex BN11 nizing the XIV Pan American Congress on rheumatic diseases taking place in Döppersberg 20, 42103 Wuppertal, Germany — Being active across Germany, 1TF, United Kingdom — The Pfizer Celebrex (celecoxib), Bextra (valdecoxib Lima, Peru from 19 to 24 August, 2006. The organizing committee will offer the our self-help association is concerned with the symptomatology of lupus erythema- tablets), and Dynastat (parecoxib sodium) exhibit features a business center, a mes- state of the art of the most important topics in the speciality, an ACR review course todes and is engaged in supporting patients suffering from this disease. We organ- sage center, a live quiz, and a series of scientific panels with an associated quiz and a top-quality closure symposium in Cuzco and Macchu Picchu—the fabulous ise symposiums and workshops held by physicians and other experts. Our more contest. In addition, interactive PC modules contain scientific panels, abstracts, land of the INCAS—giving the visitors the opportunity to contemplate the mag- than 85 groups care for our patients on a regional level. In addition, we initiate and and animations. These introduce delegates to the latest data on the COX-2 specif- nificence of one of the ancient world's most developed cultures. Please come to our participate on vast medical studies. Our patroness is Mrs. Karin Clement, wife of ic inhibitors, Celebrex, Bextra, and Dynastat. Visit the booth for more product in- booth in order to receive all the information need to participate and to gain special the German Minister of Economy and Labour.
advantages as one of the first registered members.
PHARMACIA DIAGNOSTICS . . . . . . . . . . . . . . 17/45
TRB CHEMEDICA INTERNATIONAL SA . . . . . . . . . . . 17/08
2225 Faraday Ave, Suite F, Carlsbad, CA 92008, USA — The MagneVu Munziger Strasse 7, 79111 Freiburg, Germany — Pharmacia Diagnostics 12 rue Michel Servet, P.O. Box 352, 1211 Geneva 13, Switzerland — Diac- MV1000 MRI provides high-resolution images from a compact and rugged office- develops, manufactures, and markets complete blood test systems for diagnosis and erein is an interleukin-1 inhibitor with anti-osteoarthritic and cartilage matrix based system. The system is used by rheumatologists at the point of care to identify monitoring of allergy and autoimmune diseases. Around 1,000 people are employed stimulating properties. The beneficial effects of diacerein on joint pain and function the presence of erosive and inflammatory joint disease, track disease progress, and by Pharmacia Diagnostics, which has subsidiaries in 18 countries. The highest- have a slow onset of action, becoming significant 30-45 days after the beginning of monitor response to treatment. The MV1000 helps differentiate between synovitis, quality autoimmune diagnostics has been always a demand of Pharmacia Diagnos- the treatment. The structural activity of diacerein has been shown in vitro and in osteitis (or bone edema), and bone erosions, and it helps determine which patients tics. The production of autoantigens strictly follows cGMP guidelines. The high animal models of osteoarthritis. A long-term clinical study was conducted to inves- require more aggressive treatment with RA biologics. The system is easy to oper- standard of diagnostic kits made Pharmacia Diagnostics the European leader in its tigate the structure-modifying effects of diacerein. This study suggests a slowing ate, measures 3 ft square, plugs into normal wall power, and requires no special of- effect of diacerein on the joint-space narrowing in hip osteoarthritis and the good fice set-up.
long-term safety profile of diacerein. Diacerein is marketed in several European 29 avenue du Sidobre, Les Fontaines, 81106 CASTRES, France — Structum Theaterstrasse 6, 22880 Wedel, Germany — Metoject/Metex (methotrexate 500 mg, a slow-acting drug for osteoarthritis, provides an overall management of WISEPRESS ONLINE BOOKSHOP LTD . . . . . . . . . . . 12/34
prefilled syringes) registered in Germany and several European countries offer the the chondrocyte, supplies the key component of the cartilage matrix, and makes up The Old Lamp Works, 25 High Path, Merton Abbey, SW19 2JL London, following advantages: indications (RA, PsA, Psoriasis and JIA); applications (IM, a global pharmaceutical approach. Structum 500 mg perfectly demonstrates that it United Kingdom — Wisepress Online Bookshop ltd is pleased to present a dis- IV, and subcutaneous—enclosed s.c. cannula); and concentration (10 mg/mL). Use is the disease-modifying treatment with a significant improvement in pain relief, play of publications chosen especially for EULAR 2004 from the world's leading Metoject/Metex and combine the advantages of the parenteral MTX route: better functional impairment, decrease in NSAID intake and patient's quality of life. The publishing houses. All the books on display can be ordered/bought directly at the bioavailability, fewer GI side effects, avoiding weekly visits of the patient.
dosage regimen of Structum 500 mg is simple: two capsules a day.
stand. We can also order you free sample copies of the journals on display and take subscription orders. Whatever your book requirements, Wisepress will be happy to PURDUE / MUNDIPHARMA /
12850 Middlebrook Rd, Suite 1, Germantown, MD 20874, USA — help—whether you are an author seeking a publisher or you're having difficulty ob- NAPP INDEPENDENT ASSOCIATED COMPANIES . . . . 12/19 + 12/29
Founded in 1990, Medispec develops, manufactures, and markets high-tech med- taining a title, our professional staff will assist you.
Cambridge Science Park, Milton Road, CB4 0GW, United Kingdom — ical equipment for the fields of orthopedics, traumatology, urology, and urogynecol- The Purdue/Mundipharma/Napp Independent Associated Companies are deter- ogy. Medispec provides advanced, high-quality products that comply with the WYETH PHARMACEUTICALS . . . . . . . . . . . . . . 12/40
mined to assist physicians in improving the functionality and quality of patients' worldwide standards of today's marketplace. Medispec has a proven track record of 500 Arcola Road, Collegeville, PA 19426, USA — Wyeth Pharmaceuticals lives. Using innovation in the development of potent opioids and educational part- delivering high performance Shock Wave Therapy products to international med- has leading products in the areas of women's health care, cardiovascular disease, nerships, these independent companies aim to break down the barriers blocking ical institutions. We customize solutions that meet our client's specific medical and central nervous system, inflammation, hemophilia, oncology, and vaccines. Wyeth the path to effective pain management and to encourage the appropriate use of business requirements, ensuring that they receive the highest quality, reliability, is one of the world's largest research-driven pharmaceutical and health care products opioid analgesics.
and cost efficiencies available.
companies. It is a leader in the discovery, development, manufacturing, and mar-keting of pharmaceuticals, vaccines, biotechnology products, and nonprescription RHEUMATOLOGY NEWS . . . . . . . . . . . . . . . 17/27
medicines that improve the quality of life for people worldwide.
60-B Columbia Road, Morristown, NJ 07960, USA — RheumatologyNews is an independent newspaper that provides the practicing specialist with timely and relevant news and commentary about clinical developments in the field Friday • Saturday
June 11 & 12, 2004 • Berlin
5TH ANNUAL MEETING & EXHIBITION
The EULAR 2004 Organising Committee wishes to express
MERCK SHARP & DOHME
its gratitude to all satellite symposia organisers and
EULAR/Bristol-Myers Squibb Young Investigator Award Cyber café, Run & Walk for Arthritis, pads & pens exhibitors as well as to the following sponsors:
Unrestricted Educational Grant Business Centre & Message Centre EULAR / ABBOTT Abstract Awards, Abstract Book, FinalProgramme, Palm Information System, Pocket Pro- ROCHE / GLAXOSMITHKLINE
gramme, Congress Bags, EULAR e-Sponsoring, Unre- Coffee breaks Wednesday 9 and Saturday 12 June Speakers' preview room stricted Educational Grant ESSEX PHARMA GmbH
Coffee breaks Thursday 10 and Friday 11 June Friday • Saturday
DHEA Improves Well-Being, Libido in SLE
levels of HDL cholesterol and increasedlevels of insulin-like growth factor (IGF-I). There were no effects on bone density Dehydroepiandrosterone treatment versity Hospital, Sweden, and colleagues months. Quality of life was assessed at base- or disease activity and no serious side ef- improved well-being and libido in randomized 41 women with SLE to receive line, 6 months, and one year. At 6 months, fects. Side effects included mild hirsutism, a small study of women with sys- either DHEA or placebo treatment for 6 the patients' partners also completed a ques- weight gain, and skin changes.
temic lupus erythematosus, Swedish re- months. Women in the DHEA group re- tionnaire assessing mood and behavior.
Dr. Nordmark concluded that "DHEA searchers reported at the 5th Annual Eu- ceived either 20 mg or 30 mg daily, based Normal serum DHEA levels were can be offered to women with SLE where ropean Congress of Rheumatology.
on their age: Those 46 and older received achieved with treatment. Self-rated mea- mental stress or impaired sexuality con- Women with systemic lupus erythe- 20 mg DHEA daily; those 45 and younger sures of mental well-being and libido im- stitutes a problem." matosus (SLE) have below-normal levels of received 30 mg DHEA daily. Women in proved significantly, although self reports dehydroepiandrosterone (DHEA). Levels both the placebo and treatment groups also of physical function and physical well-be- EULAR Thanks Its Corporate Members
are further suppressed with glucocortico- received 5 mg prednisolone daily.
ing did not improve. The partners report- coid treatment.
After 6 months, the trial became an open- ed that study participants "got more done" Gunnel Nordmark, MD, of the Depart- label study and all 37 continuing partici- ment of Medical Sciences at Uppsala Uni- pants received DHEA for an additional 6 DHEA use was associated with lowered Amgen (Europe) AG
Aventis Pharma SA
Boehringer Ingelheim International GmbH
Eli Lilly & Company
8th EULAR Postgraduate Course in Rheumatology
Assistenzberufe fur Rheumatologie e. V.
Helsinn Healthcare SA
Prague, Czech Republic
Hoffmann-La Roche Ltd
IBSA Institut Biochimique SA
Janssen Pharmaceutica N.V.
28 November 2004 – 3 December 2004
Kyphon Europe BVBA
Merck & Co., Inc.
Prof. José Antonio P. da Silva, Portugal Novartis Pharma AG
Opfermann Arzneimittel GmbH
(Chairperson of the EULAR Standing Committee on Education and Training) Pfizer Pharmaceutical Group, Pfizer, Inc.
Prof. Joachim R. Kalden, Germany Rotta Research Laboratorium SpA
(Past-President of EULAR) Prof. Karel Pavelka, Czech Republic TRB Chermedica International SA
(Immediate Past-General Secretary of EULAR) Prof. Jiri Vencovsky, Czech Republic(Member of the Scientific Programme Committee of the annual EULAR Congress)Mr. Fred Wyss, Switzerland The EULAR Congress News
(Executive Director of EULAR) The Official Newspaper of the 5th Annual European Congress ofRheumatology EULAR Executive Secretariat Witikonerstrasse 15 Prof. Josef S. Smolen Tel: + 41 1 383 96 90 – Fax: + 41 1 383 98 10 EULAR PRESIDENT ELECT
Prof. Tore K. Kvien
CHAIRPERSON OF THE SCIENTIFIC
Prof. Gerd R. Burmester, Germany PRESIDENT, LOCAL ORGANISING COMMITTEE
The Course venue
Prof. Wolfgang L. Gross Budejovickà 14/743 EULAR EXECUTIVE DIRECTOR
CS-1400 00 Prague 4 – Michle Tel: + 420 261 092 111 – Fax: + 420 261 261 846
The hotel ILF is conveniently located in a quite zone of Prague 4 and is linked to the centre of Prague by metro from Budejovickà station (opposite the hotel). The EDITORS
Mary Jo Dales, Kathryn DeMott
trip to the centre of town is about 10 minutes. All rooms have private bathrooms,television and telephone. The hotel belongs partly to the Czech Institute for Post- WRITERS
Bruce Jancin, Martha Kerr, Diana
graduate Medical Training of Czech Ministry of Health and is specialised in organ- Mahoney, Peggy Peck, Nancy Walsh ising medical conferences. A library with Internet facilities is available. The hotel DIRECTOR OF OPERATIONS
also offers a guarded car park.
DIRECTOR OF PRODUCTION/MANUFACTURING
Arrival on Saturday, 27 November 2004 Every hour, 09.00 – 19.00, buses will leave the airport to the Hotel ILF.
Louise A. Lynch
Departure on Saturday, 4 December 2004 Every hour, 08.00 – 17.00, buses will leave the hotel ILF to the airport.
Copyright 2004European League Against Rheumatism A taxi from the airport to the hotel will cost about Euro 25-30.
EULAR Executive SecretariatWitikonerstrasse 15CH-8032 Zürich The Course
The course fee of Euro 600 includes tuition, accommodation in single rooms and • T +41 1 383 96 90 all meals (breakfast, lunch, dinner and coffee breaks). If you wish to be accompa- • F +41 1 383 98 10• email@example.com nied by your partner/spouse, limited double room accommodation is available for Produced and distributed for EULAR by Euro 900, however, your spouse/partner cannot participate at the scientific pro- INTERNATIONAL MEDICAL NEWS GROUP, Elsevier. All gramme of the course.
rights reserved. No part of this publication may bereproduced or transmitted in any form, by anymeans, without prior written permission of Programme of the Course
A draft programme with topics will be on the EULAR website as of 15 May 2004.
EULAR. The opinions expressed in this publica-tion are those of the presenters and authors, anddo not necessarily reflect the views of EULAR.
Comité editorial nacional Dra. Nora Garro Bardobiaro / UAM-Iztapalapa Revista mexicana de estudios sobre la Cuenca del Pacífico Departamento de EconomíaMtro. Alfredo Romero Castilla / UNAM, Facultad de Ciencias Políticas y Sociales Enero • Junio de 2007 • Tercera Época • Volumen 1 • Número 1 Dr. Juan González García / Universidad de Colima, CUEICPDr. José Ernesto Rangel Delgado / Universidad de Colima